Peptide Compass
A regulatory status app that tells consumers which peptides — BPC-157, GHK-Cu, Ipamorelin, and others — are legal, prescription-only, or compounding-restricted in their state, and routes them to compliant telehealth clinics.
men using or considering peptide therapy who want to stay on the right side of FDA and state rules
- State-by-state peptide legality database updated when FDA acts (push alerts on changes)
- Watchlist feature where you track the peptides you use and get notified the moment one moves
- Vetted telehealth clinic directory with state license verification and pricing
- Plain-language explainers of what each peptide is FDA-approved for vs. investigational
BPC-157 just got added to an FDA compounding list — the line between 'wellness supplement' and 'regulated drug' is shifting in real time, and most peptide users have no idea which side they're currently on or whether their next refill is legal.
FDA actively reclassifying BPC-157 (Category 2, April 2026) and PCAC meeting July 23-24 drives real-time regulatory confusion; multiple dedicated peptide-regulatory sites already serve this audience showing validated interest.Is BPC-157 Legal in 2026? The FDA Reclassification, Explained ↗Regulatory Tracker — FDA Peptide Status, PCAC Outlook, State Variance ↗
At least four direct competitors already operate state-by-state peptide regulatory trackers (PeptidesBeat, PeptideStatus, PeptidesScholar, PeptideJournal), plus Vektor Health covers the topic — the specific 'compliance routing to telehealth clinics' angle is incremental, not greenfield.State-by-state peptide legality | Peptide Status ↗Peptide Legal Status by State — 50 State Guide (2026) ↗Are Peptides Legal? State-by-State Guide (2026) | PeptideJournal ↗
Peptide telehealth subs run $149–$399/month and patients clearly pay $150–$1,200/month for therapy, so referral commissions are plausible — but most users land on free trackers first, and trust in affiliate-linked clinics is unproven.Peptide Therapy Cost Guide 2026: Clinics, At-Home & Compounding ↗Peptide Therapy Costs: Monthly Expense Guide | Telehealth Ally ↗
Regulatory volatility (FDA April 2026 reclass, PCAC July 2026, ongoing state-board actions) guarantees a stream of updates worth tracking — but the same volatility means data may go stale weekly and state boards occasionally contradict federal guidance.FDA Briefing Document Pharmacy Compounding Advisory Committee (PCAC) ↗Certain Bulk Drug Substances for Use in Compounding ↗
MVP (scraping/curating FDA + 50 state pharmacy board sources + telehealth directory) is buildable in weeks, but perpetual update cycles (per PeptidesBeat: 24h for FDA, 90-day rolling for states) plus legal-disclaimer complexity around 'routing' raise real ongoing ops cost.Regulatory Tracker — FDA Peptide Status, PCAC Outlook, State Variance ↗